MC
GBT

Marcus Capital’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Marcus Capital’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-31,200
Closed -$969K – 44
2017
Q3 		$969K Sell
31,200
-34,150
-52% -$960K 1.38% 32
2017
Q2 		$1.79M Buy
65,350
+13,350
+26% +$397K 1.53% 32
2017
Q1 		$1.92M Buy
52,000
+21,900
+73% +$552K 1.79% 28
2016
Q4 		$435K Hold
30,100
– – 0.47% 43
2016
Q3 		$694K Hold
30,100
– – 0.67% 44
2016
Q2 		$499K Buy
+30,100
New +$607K 0.53% 45

Other funds holding GBT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Marcus Capital's GBT Position: Q4 2017 in Review

Marcus Capital sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2017, closing a stake of 31,200 shares — an estimated $969K sold.

Marcus Capital first reported a position in GBT in Q2 2016 and held it in 6 quarters. The position peaked at $1.92M in Q1 2017. 157 funds tracked by Wall St. Rank hold GBT as of Q4 2017.

  • Marcus Capital reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2017 after selling out during the quarter.
  • Marcus Capital sold 31,200 Global Blood Therapeutics, Inc. shares in Q4 2017, an estimated $969K.
  • Marcus Capital first reported a position in Global Blood Therapeutics, Inc. in Q2 2016 and held it in 6 quarters.
  • Marcus Capital's Global Blood Therapeutics, Inc. position peaked at $1.92M in Q1 2017.
  • 157 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2017.

Based on Marcus Capital's 13F filing for Q4 2017, filed 7 Feb 2018.